Long‐term (up to 18 years) effects on GH/IGF‐1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH‐secreting pituitary adenoma responsive to SSTa
Jean Christophe Maiza(Hôpital Rangueil), Philippe Caron(Hôpital Larrey), Maxime Cournot(Centre Hospitalier Universitaire de Toulouse), F. Loubes-Lacroix(Hôpital Rangueil), Maria Matta(Hôpital Rangueil), Antoine Bennet(Hôpital Rangueil), F. Donadille(Hôpital Rangueil), Delphine Vezzosi(Université Toulouse III - Paul Sabatier)
Cited by 121
Related Papers
Constitutive Activation of PKA Catalytic Subunit in Adrenal Cushing's Syndrome
|New England Journal of Medicine|2014|434
Ketoconazole in Cushing's Disease: Is It Worth a Try?
|The Journal of Clinical Endocrinology & Metabolism|2014|288
Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study
|Annals of Oncology|2015|257
Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies
|European Journal of Endocrinology|2005|183
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study
|The Journal of Clinical Endocrinology & Metabolism|2019|180